[144] Kiniksa Pharmaceuticals International, plc SEC Filing

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) filed a Form 144 proposing the sale of 50,129 Class A ordinary shares. The filing shows the shares were acquired and are to be sold on 08/13/2025 via an employee stock option exercise with payment described as Broker Payment for Cashless Exercise. The broker listed is Charles Schwab & Co., Inc. and the aggregate market value is $1,670,468.00. The filing reports 43,472,928 shares outstanding, so the offered block equals about 0.12% of outstanding shares. The document also discloses a sale by Thomas Malley of 49,407 shares on 08/12/2025 for $1,600,641.00. Several identifying fields (CIK/CCC and filer contact/name fields) are not populated in the provided content.

Positive

• Disclosure completeness on transaction: The Form 144 lists acquisition date, transaction type, broker, sale date, number of shares, and aggregate market value.
• Limited size relative to outstanding shares: 50,129 shares represent approximately 0.12% of the reported 43,472,928 shares outstanding, suggesting limited dilution or market impact from this block.

Negative

• Missing filer identifiers/contact info: The provided content does not populate CIK/CCC or the filer contact and name fields, reducing identifiability of the reporting party in this extract.

Insights

Securities Analyst

TL;DR: Proposed sale of 50,129 shares (~0.12% outstanding) via cashless exercise; appears routine with limited market impact.

The Form 144 discloses a contemporaneous acquisition and proposed sale of 50,129 Class A ordinary shares on 08/13/2025, recorded as an employee stock option exercise with broker payment for a cashless exercise. Using the reported outstanding shares (43,472,928), the position represents roughly 0.12% of float, indicating minimal direct dilution or market pressure from this single block. The aggregate market value is reported as $1,670,468.00 and the listed broker is Charles Schwab & Co., Inc. A sale the day prior (Thomas Malley, 49,407 shares for $1,600,641.00 on 08/12/2025) is also disclosed, showing recent related sales activity in similar size. Overall, this filing reads as a routine insider liquidity event rather than a material corporate development.

Corporate Governance Expert

TL;DR: Filing includes standard Rule 144 disclosures and a representation about material adverse information; some issuer/filer identifiers are missing in provided text.

The submission contains the standard attestation that the person selling does not know of undisclosed material adverse information about the issuer and includes the required transaction details (acquisition date, nature of acquisition, broker, sale date, and aggregate value). It documents that the securities were acquired and disposed on the same date via an employee option exercise and a broker cashless payment. The provided content omits populated fields for filer identifiers and contact details, which limits verification of the filer identity in this extract. From a governance and disclosure-compliance perspective, the form contains the essential transaction elements, but the missing identifiers in the supplied content reduce completeness for third-party review.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A ordinary shares	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	50129	1670468.00	43472928	08/13/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A ordinary shares	08/13/2025	Employee Stock Option Exercise	Kiniksa Pharmaceuticals International, plc			50129	08/13/2025	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Thomas Malley 100 Hayden Avenue Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	08/12/2025	49407	1600641.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the KNSA Form 144 propose to sell?

50,129 Class A ordinary shares of Kiniksa Pharmaceuticals International, plc are proposed for sale.

When is the approximate date of sale reported in the filing?

The approximate date of sale is 08/13/2025.

What is the aggregate market value of the shares reported in the Form 144?

The aggregate market value is reported as $1,670,468.00.

How were the shares acquired according to the filing?

The shares were acquired on 08/13/2025 through an Employee Stock Option Exercise, with payment noted as Broker Payment for Cashless Exercise.

Were any prior sales reported within the past three months in this filing?

Yes. The filing shows Thomas Malley sold 49,407 shares on 08/12/2025 for $1,600,641.00.

Which broker is listed for the proposed sale?

The broker listed is Charles Schwab & Co., Inc. (address shown as 3000 Schwab Way, Westlake TX 76262).